Basque
English
Afrikaans
Albanian
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bulgarian
Catalan
Chinese (Simplified)
Chinese (Traditional)
Croatian
Czech
Danish
Dutch
Estonian
Filipino
Finnish
French
Galician
Georgian
German
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Malay
Maltese
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Thai
Turkish
Ukrainian
Urdu
Vietnamese
Welsh
Yiddish
Aipagarrienak EAHADen XIV
HOPE-B terapia genetikoaren 3. faseko azken analisia: Etranacogene Dezaparvovec-en egoera egonkorrean eraginkortasuna eta segurtasuna B hemofilia larria edo moderatua duten helduetan.
Wolfgang Miesbach1; Frank WGLeebeek2; Michael Recht3; Nigel S. Giltza4; Susan Lattimore3; Giancarlo Castaman5; Michael Coppens6; David Cooper7; Sergio Slawka7; Stephanie Verweij7; Robert Gut7; Ricardo Dolmetsch7; Yanyan Li8; Paul E. Monahan8; Steven W. Pipe9
HOPE-B Ikertzaileak1; Frankfurt, Frankfurt, Alemaniako Unibertsitate Ospitalea2; Erasmus MC, University Medical Center Rotterdam, Herbehereak3; Oregon Health & Science University, Portland, OR, Estatu Batuak4; Ipar Carolinako Unibertsitatea, Chapel Hill, NC, Ameriketako Estatu Batuak5; Odoljarioen Nahasteen eta Koagulazio Zentroa, Careggi Unibertsitate Ospitalea, Florentzia, Italia6; Amsterdam Unibertsitateko Medikuntza Zentroak, Amsterdameko Unibertsitatea, Amsterdam, Herbehereak7; uniQureBV, Amsterdam, Herbehereak/uniQure Inc. Lexington, MA, AEB8; CSL Behring, Prusiako erregea, PA, Estatu Batuak9; Michigango Unibertsitatea, Ann Arbor, MI, Estatu Batuak
KONTSEILU HARREMANETAN
